All News
BSR Guideline on Management of Sjogren’s Syndrome
Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficient interventions for those affected with mucosal or systemic manifestations.
Read Article
ICYMI: Vasculitis Pearls
Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks. They gave us what we really want from these talks – personal opinions and approaches that go beyond the guidelines. They really dropped a selection of pearls on us and I wanted to share a few of these with you.
Read Article
Biopsy Results in Sjogren's Syndrome
A prospective study from the Netherlands analyzed the comparative value of simultaneous labial and parotid salivary gland biopsies performed in patients with sicca complaints and suspected Sjogren's syndrome (SjD).
Burnout or Retire
Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv. Is it time to worry about burnout and those who are leaving healthcare?
https://t.co/p8ek7A8HAk https://t.co/nH5fDywLic
Dr. John Cush RheumNow ( View Tweet)
PNAS: Autoimmunity against MDA5 induces fibrotic ILD in mice. In this murine model of dermatomyositis, treatment with either anti-CD4 or anti-IL-6 receptor antibody ameliorated the MDA5-induced fibrotic ILD. https://t.co/CahyGfTn4g https://t.co/lfpdgEvGmx
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Sex Disparities in PsA/SpA
https://t.co/55zwjR8mNR https://t.co/fhhekNpHVA
Dr. John Cush RheumNow ( View Tweet)
ILD Onset in MDA-5 Dermatomyositis
MDA5 antibody-positive DM is a rare, aggressive and progressive subtype of DM. Its' severity is dependent on the development of progressive ILD, manifesting as either RPILD and CILD.
https://t.co/08wAYj06DH https://t.co/TQWHGR27O9
Dr. John Cush RheumNow ( View Tweet)
World Congress on OP, OA & MSK Disorders
Bone and musculoskeletal disease researchers and physicians from around the world will meet today in London for the opening of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
https://t.co/kzvWD4Rmki https://t.co/PJQREsJO9v
Dr. John Cush RheumNow ( View Tweet)
Neuropsychiatric SLE - 2/3 Improved at 12 Months
The management and outcomes of neuropsychiatric systemic lupus erythematosus (NPSLE) can be challenging as there is limited data.
https://t.co/p0GEtkUTdt https://t.co/EZhjH6PxWQ
Dr. John Cush RheumNow ( View Tweet)
TNFi mAbs, JAKi, –IL-17 are protective against Anterior Uveitis (AU) in AxSpA. Metanalysis of 44 RCTs shows AU IR:
- TNF mAbs: 4.1
- etanercept 5.4
- IL-17i: 2.8
- JAKi: 1.5
- placebo: 10.8 https://t.co/sxqCXkD0up https://t.co/XWXUPmCtZr
Dr. John Cush RheumNow ( View Tweet)
Of 375 #Gout pts D/C pegloticase after a median of 8 infusions (taken 112days (max 1,240d). Only 73% had SUA < 6 during pegloticase. After D/C 84% went on ULT (63% allopurinol; 34% febuxostat; after mean 92d); after ≥ 30 days), 51% achieved SUA < 6 https://t.co/unkvt1whrs https://t.co/DgVpBgKXcm
Dr. John Cush RheumNow ( View Tweet)
Mental health in 1150 adolescents & young adults w/ juvenile idiopathic arthritis (age 15.6 yrs; Dz duration 7.2 yrs, 43% oligo-, 26% polyarthritis): 30% reported suicidal thoughts, 19% mod-severe depressive/anxious Sxs (moreso in Females OR 2.33) https://t.co/THW1IMqZpa https://t.co/IU2Kr3efYj
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Top 5 Clinical Pearls in RA Management
https://t.co/zWRXzHTtIo https://t.co/rbitB9oWQG
Dr. John Cush RheumNow ( View Tweet)
Canadian OBRI study in 692 RA pts shows pts treated w/ triple DMARD (MSH) stayed on Rx longer (15 mos) compared to MTX+LEF (9.6 mos); not significant but MTX/SSZ/HCQ had signif lower DAS28 @ 6 mos (3.4 vs 3.9) & at 12 mos (3.2 vs 3.5, p=0.0005) https://t.co/ieHeXvgj3n https://t.co/MEMA1nrUpy
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us 4/16 for Tuesday Night Rheumatology at 6:30pm ET. This week we'll be focusing on Vasculitis Mavens with:
Vasculitis & Pregnancy - Catherine Sims, MD
GPA Management in 2024 - Anisha Dua, MD, MPH
Treat to Target in Vasculitis - Philip Seo, MD
https://t.co/6IaCdCodGf https://t.co/HlZ8OiZWc4
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA: SLE Review
Drs.Siegel & Sammaritano (from HSS in NYC) published an impressive overview of SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.
https://t.co/byr1hRA6rV https://t.co/wZeIdfTlH0
Links:
Dr. John Cush RheumNow ( View Tweet)
Pearl: Patients with persistent TMJ pain are more likely to have fibromyalgia than inflammatory or degenerative arthritis (as the underlying cause of their chronic pain) https://t.co/G43rxKVHus https://t.co/4mCu7b0PGn
Dr. John Cush RheumNow ( View Tweet)
IL-1 recept accessory protein (IL1RAP) shown to block mediators (IL-1, IL33, IL36) that may drive systemic sclerosis. In vitro, IL1RAP inhibited fibroblasts and endothelial cells; in mouse models of SSc anti-IL1RAP decr dermal & pulmonary fibrosis. https://t.co/6YE02P4rjR https://t.co/mzw7t88Jzl
Dr. John Cush RheumNow ( View Tweet)
SLE in JAMA (authored by Drs Siegel & Sammaritano at HSS), impressive, full-read review, Covers:
- Presentations: skin, Jts, brain, heme, etc
- Treatments
- Prognosis
- Complications: CV, infx, CA
- FAQs
https://t.co/7WHYK3DgIf https://t.co/pC2MSCpn52
Links:
Dr. John Cush RheumNow ( View Tweet)
Polycyclic Aromatic Hydrocarbons Increase Lupus Risk
A case-controlled study shows environmental exposure to polycyclic aromatic hydrocarbons (PAH) may increase the risk of developing systemic lupus erythematosus (SLE).
https://t.co/AuYazGtamr https://t.co/S96LAuGtba
Dr. John Cush RheumNow ( View Tweet)